Catalyst Award
Suzanne Paradis, PhD / Brandeis University
The team will test the safety and efficacy of using gene therapy to deliver Sema4D as a novel therapy for drug-resistant epilepsy.
CURE Epilepsy Award
Maxime Baud, MD, PhD / University of Bern
For this project, they would like to test whether similar results could be obtained for people with genetic generalized epilepsy using a novel, minimally invasive EEG system.
Taking Flight Award
Jeffrey Calhoun, PhD / Northwestern University
This research will develop a new method to rapidly determine which (if any) genetic variants near SCN1A, an important epilepsy gene, alter SCN1A gene expression.
CURE Epilepsy Award
Annaelle Devergnas, PhD / Emory University
The hypothesis for this project is that frontal seizures disrupt the normal function of the PPN, leading to changes in sleep, and that manipulating PPN activity might restore normal sleep activity.
Taking Flight Award
Gerben van Hameren, PhD / Dalhousie University
Dr. van Hameren will study the damage to mitochondria caused by spreading depolarization and whether blocking this damage with a drug can prevent the development of post-traumatic epilepsy.
CURE Epilepsy Award
Juliet Knowles, MD, PhD / Stanford School of Medicine
For this project, the team will study whether HDACIs can prevent myelin plasticity and seizure progression in a mouse model of LGS.
CURE Epilepsy Award
Gordon Buchanan, MD, PhD / University of Iowa Medicine
Dr. Buchanan’s group will examine whether a signaling molecule called serotonin drives this time-of-day vulnerability to SUDEP.
Taking Flight Award
William Tobin, PhD / The University of Vermont and State Agriculture
Dr. Tobin will test strategies to optimize cutting-edge gene and drug therapies by selectively targeting the most severely affected cells and brain networks in a mouse model of KCNT1-related epilepsy.
Catalyst Award
James Pauly, PhD / University of Kentucky
Having obtained promising initial results in mouse models, this project will now test the safety and brain distribution of this novel therapy in a canine model.
